Epidemiologic characteristics of users of the Cervical Cancer Prevention Program in Uruguay
Keywords:
UTERINE CERVICAL NEOPLASMS, URUGUAYAbstract
For the first time in Uruguay a sample of 96.858 women, users of the Cervical Cancer Prevention Program was analized in order to obtain an epidemiologic characterization. Prevalence of results associated with cervical cancer was 1,20% in the studied population. Epidemiologic factors of cervical cancer associated with Papanicolaou test results were Sexually Transmitted Diseases, HPV (Human papillomavirus) and HIV (human immunodeficiency virus), smoking and lack of prevention control test.
Prevention should be wider in women with who do not have the resources to meet their basic needs.
References
1) Vasallo J, Barrios E, De Estefani E, Ronco A. II Atlas de Incidencia del cáncer en el Uruguay 1996-1997. Montevideo: Comisión Honoraria de Lucha Contra el Cáncer, 2001: 16.
2) Vasallo J, Barrios E. II atlas de mortalidad por cáncer en el Uruguay. Montevideo: Comisión Honoraria de Lucha contra el Cáncer, 1999.
3) Reagan JW, Seidemann IL, Saracusa Y. The cellular morphology of carcinoma in situ and dysplasia or atypical hyperplasia of uterine cervix. Cancer 1953; 6(2): 224-34.
4) Broders AC. Carcinoma in situ contrastes with benign penetrating epithelium. JAMA 1932; 99: 1670.
5) Richart RM. Cervical intraepithelial neoplasia: A review. In: Sommers SC, ed. Pathology Annual, Vol 8. Connecticut: Norwalk, Appleton Century-Crofts, 1973: 301.
6) National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytolgical diagnoses. JAMA 1989; 262(7): 931-4.
7) Vasallo J, Barrios E. Actualización ponderada de los factores de riesgo del cáncer. Montevideo: Comisión Honoraria de Lucha contra el Cáncer, 2003: 87.
8) DiSaia PJ, Creasman WT. Enfermedad preinvasora del cuello uterino. In: DiSaia PJ, Creasman WT. Oncología Ginecológica Clínica. 5 ed. Madrid: Harcourt Brace, 1999: 1-32.
9) Ostor AG. Natural history of cervical intraepitelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12(2): 186-92.
10) Hosmer DW, Lemeshow S. Applied Logistic Regression. Wiley Series of Probability and Statistics. Applied probability and statictics section. New York: Wiley, 1999.
11) SAS Institute Inc. Reference guide: versión 6.12. Cary, North Carolina: SAS Institute, 1998.
12) Schottenfeld D, Fraumeni, JF. Cancer epidemiology and prevention. New York: Oxford Press, 1996: 1090-116.
13) Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55(4): 244-65.
14) Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. International Agency for Research on cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-27.
15) Moreno V, Bosch FX, Muñoz N, Neijer CJ, Shah KV, Walboomers JM, et al. International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case control study. Lancet 2002; 359(9312): 1085-92.
16) Smith JS, Green J, Berrington de González A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361(9364): 1159-67.
17) Valente PT, Hanjani P. Endocervical neoplasia in long term users of oral contraceptives: clinical and pathologic observations. Obstet Gynecol 1986; 6(5): 695-704.
18) Parazzini F, la-Vecchia C, Negri E, Maggi R. Oral contraceptive use and invasive cervical cancer. Int J Epidemiol 1990; 19(2): 259-63.
19) Delgado-Rodríguez M, Sillero-Arenas M, Martin-Moreno JM, Galvez-Vargas R. Oral contraceptives and cancer of the cervix uteri. A meta analysis. Acta Obstet Gynecol Scand 1992; 71(5): 368-76.
20) Hellberg D, Valentin J, Nilsson S. Long-term use of oral contraceptives and cervical neoplasia: an association confounded by other risk factors? Contraception 1985; 3(4): 337-46.
21) Brinton L. Oral contraceptives and cervical neoplasia. Contraception 1991; 43(6): 581-95.
22) Miller K, Blumenthal P, Blanchard K. Oral contraceptives and cervical cancer: critique of a recent review. Contraception 2004; 69(5): 347-51.
23) Fuenzalida S, Paez Avalos G, Gutiérrez L, Rodríguez J, Pobrete C, Ureta C, et al. Citología cervical en dos estratos socioeconómicos. Bol Hosp San Juan de Dios 1993; 40(3): 160-3.
24) Cortés E, Rojas M, Reyna R, Garza R, Leal C. Algunos factores epidemiológicos en el cáncer cérvico uterino. Rev Med IMSS 1995; 33(2): 177-82.
25) Dabancens A, López J, Molina R, Thomas D. Análisis de las asociación entre uso previo de anticonceptivos e Incidencia de cáncer cervico uterino en mujeres del área norte de Santiago. Rev Chil Obstet Ginecol 1986; 51(2): 188-94.
26) Huggins G, Zucker P. Oral contraceptives and neoplasia: 1987 update. Fertil Steril 1987; 41(5): 733-61.
27) Acladious NN, Sutton C, Mandal D, Hopkins R, Zaclama M, Kitchener H. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepitelial neoplasia. Int J Cancer 2002; 98(3): 435-9.
2) Vasallo J, Barrios E. II atlas de mortalidad por cáncer en el Uruguay. Montevideo: Comisión Honoraria de Lucha contra el Cáncer, 1999.
3) Reagan JW, Seidemann IL, Saracusa Y. The cellular morphology of carcinoma in situ and dysplasia or atypical hyperplasia of uterine cervix. Cancer 1953; 6(2): 224-34.
4) Broders AC. Carcinoma in situ contrastes with benign penetrating epithelium. JAMA 1932; 99: 1670.
5) Richart RM. Cervical intraepithelial neoplasia: A review. In: Sommers SC, ed. Pathology Annual, Vol 8. Connecticut: Norwalk, Appleton Century-Crofts, 1973: 301.
6) National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytolgical diagnoses. JAMA 1989; 262(7): 931-4.
7) Vasallo J, Barrios E. Actualización ponderada de los factores de riesgo del cáncer. Montevideo: Comisión Honoraria de Lucha contra el Cáncer, 2003: 87.
8) DiSaia PJ, Creasman WT. Enfermedad preinvasora del cuello uterino. In: DiSaia PJ, Creasman WT. Oncología Ginecológica Clínica. 5 ed. Madrid: Harcourt Brace, 1999: 1-32.
9) Ostor AG. Natural history of cervical intraepitelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12(2): 186-92.
10) Hosmer DW, Lemeshow S. Applied Logistic Regression. Wiley Series of Probability and Statistics. Applied probability and statictics section. New York: Wiley, 1999.
11) SAS Institute Inc. Reference guide: versión 6.12. Cary, North Carolina: SAS Institute, 1998.
12) Schottenfeld D, Fraumeni, JF. Cancer epidemiology and prevention. New York: Oxford Press, 1996: 1090-116.
13) Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55(4): 244-65.
14) Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. International Agency for Research on cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-27.
15) Moreno V, Bosch FX, Muñoz N, Neijer CJ, Shah KV, Walboomers JM, et al. International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case control study. Lancet 2002; 359(9312): 1085-92.
16) Smith JS, Green J, Berrington de González A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361(9364): 1159-67.
17) Valente PT, Hanjani P. Endocervical neoplasia in long term users of oral contraceptives: clinical and pathologic observations. Obstet Gynecol 1986; 6(5): 695-704.
18) Parazzini F, la-Vecchia C, Negri E, Maggi R. Oral contraceptive use and invasive cervical cancer. Int J Epidemiol 1990; 19(2): 259-63.
19) Delgado-Rodríguez M, Sillero-Arenas M, Martin-Moreno JM, Galvez-Vargas R. Oral contraceptives and cancer of the cervix uteri. A meta analysis. Acta Obstet Gynecol Scand 1992; 71(5): 368-76.
20) Hellberg D, Valentin J, Nilsson S. Long-term use of oral contraceptives and cervical neoplasia: an association confounded by other risk factors? Contraception 1985; 3(4): 337-46.
21) Brinton L. Oral contraceptives and cervical neoplasia. Contraception 1991; 43(6): 581-95.
22) Miller K, Blumenthal P, Blanchard K. Oral contraceptives and cervical cancer: critique of a recent review. Contraception 2004; 69(5): 347-51.
23) Fuenzalida S, Paez Avalos G, Gutiérrez L, Rodríguez J, Pobrete C, Ureta C, et al. Citología cervical en dos estratos socioeconómicos. Bol Hosp San Juan de Dios 1993; 40(3): 160-3.
24) Cortés E, Rojas M, Reyna R, Garza R, Leal C. Algunos factores epidemiológicos en el cáncer cérvico uterino. Rev Med IMSS 1995; 33(2): 177-82.
25) Dabancens A, López J, Molina R, Thomas D. Análisis de las asociación entre uso previo de anticonceptivos e Incidencia de cáncer cervico uterino en mujeres del área norte de Santiago. Rev Chil Obstet Ginecol 1986; 51(2): 188-94.
26) Huggins G, Zucker P. Oral contraceptives and neoplasia: 1987 update. Fertil Steril 1987; 41(5): 733-61.
27) Acladious NN, Sutton C, Mandal D, Hopkins R, Zaclama M, Kitchener H. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepitelial neoplasia. Int J Cancer 2002; 98(3): 435-9.
Downloads
Published
2005-10-31
How to Cite
1.
Rodríguez G, Barrios E, Vasallo J. Epidemiologic characteristics of users of the Cervical Cancer Prevention Program in Uruguay. Rev. Méd. Urug. [Internet]. 2005 Oct. 31 [cited 2024 Sep. 7];21(3):200-6. Available from: https://revista.rmu.org.uy/index.php/rmu/article/view/804
Issue
Section
Original Articles
